Options for the treatment of arterial hypertension (AH) induced by chemotherapy proposed by the European Society of Cardiology (ESC) oppose the Eurasian clinical guidelines for cardio-oncology. The choice of an adequate and effective treatment regimen for VEGF (vascular endothelial growth factor)-induced hypertension remains a controversial issue in cardio-oncology and requires additional research.
No takes yet. Share an insight, caveat, or question.
Khlyamov et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: